MRTNZ

MRTNZ Investment Office · S&P 500 · The 360 Vantage

BSX · NYSE

Boston Scientific Corporation

Health Care · Medical/Dental Instruments

Reference price$45.20As of Jul 30, 2026
Market capitalization$66.98B
52-week range$42.20–$109.50
S&P 500 portfolio weight0.11%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$50.00+10.6% vs. reference
Average$62.86+39.1% vs. reference
High$89.00+96.9% vs. reference
21 Buy2 Hold0 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportNot availableSep 2026
Consensus EPS$0.802 estimates
Expected range$0.80–$0.80Low to high EPS
Dec 2026$3.31Street EPS consensus
Dec 2027$3.69Street EPS consensus
Dec 2028$4.06Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Dec 31, 2025.

MetricCurrentPrior
Revenue+19.9% YoY$20.07B$16.75B
Operating income$3.61B$2.6B
Net income$2.9B$1.85B
Operating cash flow$4.53B$3.44B
Capital expenditures($0.88B)($0.79B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

Zacks

Boston Scientific (BSX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks

Boston Scientific Q2 Earnings & Revenues Top Estimates, Stock Climbs

NASDAQ.com

Pre-Market Most Active for Jul 29, 2026 : MUU, SOFI, SKUU, SKDD, SKHY, TQQQ, NOK, BE, FCX, IONQ, BSX, F

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →

Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.